Video
Author(s):
The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.
The committee for the International Diagnostic Criteria for Multiple Sclerosis will be releasing its first update of multiple sclerosis (MS) diagnosing standards since 2010, later this year.
Jeffrey Cohen, MD, director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic, shared his inside-track knowledge of the machinations and discussions being had by the criteria-setters at the 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans this week.
Cohen sat down during CMSC to talk new criteria details, where issues lie in MS misdiagnosis, and how new forms of treatment could potentially influence diagnoses.
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA